ReNeuron Group plc Board Change (1376F)
14 Julio 2021 - 01:00AM
UK Regulatory
TIDMRENE
RNS Number : 1376F
ReNeuron Group plc
14 July 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Board Change
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces that Barbara
Staehelin has joined the Board as senior independent Non-Executive
Director with immediate effect.
Ms. Staeheli n's career in the international life sciences and
technology sectors spans over 30 years and includes consulting, CEO
and Chair roles. She has led and co-founded four life science
companies and is currently on the Board as President of the Audit
and Risk Committee and a member of the Investment Committee at
Assura Group , which operates in the health insurance sector and
which is headquartered in Switzerland. Ms. Staehelin's background
is in biochemistry and until 2006, she was a member of the Global
Executive Committee of Roche Diagnostics.
Ms. Staehelin holds a Directors Certificate from Harvard
University, USA as well as executive education in new concepts for
boards from University St. Gallen, Switzerland, health economy from
the European School for Health Economics, France and an MBA from
INSEAD Fontainebleau, France.
Iain Ross, Chairman of ReNeuron, commented: "I am delighted to
welcome Barbara to the ReNeuron Board as a Non-Executive Director.
She brings a wealth of market development experience in the medical
services and biotech sectors and a strong track record in corporate
governance. My colleagues and I look forward to working with her
during this transformational time for ReNeuron."
Disclosures in accordance with the AIM Rules
Barbara Regina Staehelin, 58, is, or has been, a director or
partner of the following companies or partnerships during the past
five years:
Current Partnerships and Directorships:
Axicos AG
Assura Holding SA
Assura SA
Assura-Basis SA
Figeas SA
ABC Invest & Medical GmbH
Dybly AG
Ava AG
Prior Partnerships & Directorships:
Keires AG
In 2009, Ms Staehelin was appointed as turnaround CEO of
SIRS-Lab GmbH, a molecular diagnostics company headquartered in
Germany. Having successfully led one funding round and the
completion of a clinical trial, in July 2012, Ms Staehelin resigned
from her position and worked her notice period. On 1 March 2013, as
a result of an inability to raise additional capital, the company
entered into a Court ordered liquidation and then was dissolved on
3 November 2013.
In 1997, Ms Staehelin became Chairman of GetWellness AG which
was voluntarily dissolved in 2006 in a solvent wind-up and the
resulting corporate entity was then put into liquidation.
Ms. Staehelin has no holding in ReNeuron.
There are no further disclosures required in accordance with AIM
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments for disease with significant unmet
needs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the central nervous system and other disorders. The
Company also has the ability through its conditionally immortalised
induced pluripotent stem cell (iPSC) platform to make allogeneic
tissue cells of choice; in-house programmes are currently focused
on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOARJMRTMTMBBIB
(END) Dow Jones Newswires
July 14, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024